BACKGROUND: The objective of this study was to assess the impact of hyperoxemia on mortality in critically ill patients with ventilator-associated pneumonia (VAP). METHODS: This observational study was performed in a 50-bed mixed intensive care unit (ICU) during a 1-year period. Quantitative microbiological confirmation was required for VAP diagnosis. Hyperoxemia was defined as peripheral capillary oxygen saturation (SpO2) ≥98%. SpO2 was hourly collected in all study patients during the whole period of mechanical ventilation. The primary objective was to assess the influence of hyperoxemia on ICU mortality. RESULTS: Ninety-three patients with VAP were all included in this study. ICU-mortality rate was 32% (30 of 93 patients). The mean percentage of time spent with hyperoxemia in survivors and nonsurvivors at ICU admission, before, after or at the time of VAP diagnosis was not significantly different. Multivariate analysis identified age, and sequential organ dysfunction assessment at the day of VAP occurrence as independent risk factors for ICU mortality [odds ratio (OR) =1.04 (95% CI, 1.01-1.08) per year, P=0.019; 1.19 (95% CI, 1.06-1.34) per point, P=0.003; respectively]. The time spent with hyperoxemia before VAP occurrence was not significantly associated with mechanical ventilation free days, or ICU length of stay. CONCLUSIONS: Hyperoxemia at ICU admission, or during ICU stay, had no significant impact on ICU mortality in critically ill patients with VAP.
BACKGROUND: The objective of this study was to assess the impact of hyperoxemia on mortality in critically ill patients with ventilator-associated pneumonia (VAP). METHODS: This observational study was performed in a 50-bed mixed intensive care unit (ICU) during a 1-year period. Quantitative microbiological confirmation was required for VAP diagnosis. Hyperoxemia was defined as peripheral capillary oxygen saturation (SpO2) ≥98%. SpO2 was hourly collected in all study patients during the whole period of mechanical ventilation. The primary objective was to assess the influence of hyperoxemia on ICU mortality. RESULTS: Ninety-three patients with VAP were all included in this study. ICU-mortality rate was 32% (30 of 93 patients). The mean percentage of time spent with hyperoxemia in survivors and nonsurvivors at ICU admission, before, after or at the time of VAP diagnosis was not significantly different. Multivariate analysis identified age, and sequential organ dysfunction assessment at the day of VAP occurrence as independent risk factors for ICU mortality [odds ratio (OR) =1.04 (95% CI, 1.01-1.08) per year, P=0.019; 1.19 (95% CI, 1.06-1.34) per point, P=0.003; respectively]. The time spent with hyperoxemia before VAP occurrence was not significantly associated with mechanical ventilation free days, or ICU length of stay. CONCLUSIONS: Hyperoxemia at ICU admission, or during ICU stay, had no significant impact on ICU mortality in critically ill patients with VAP.
Authors: Kazuhiro Tateda; Jane C Deng; Thomas A Moore; Michael W Newstead; Robert Paine; Nobuyuki Kobayashi; Keizo Yamaguchi; Theodore J Standiford Journal: J Immunol Date: 2003-04-15 Impact factor: 5.422
Authors: Carlos E O Baleeiro; Steven E Wilcoxen; Susan B Morris; Theodore J Standiford; Robert Paine Journal: J Immunol Date: 2003-07-15 Impact factor: 5.422
Authors: Dympna M P Morrow; Tahereh Entezari-Zaher; John Romashko; Ali O Azghani; Mohammad Javdan; Luis Ulloa; Edmund J Miller; Lin L Mantell Journal: Free Radic Biol Med Date: 2007-01-23 Impact factor: 7.376
Authors: Yuko Arita; Jeffrey A Kazzaz; Ansamma Joseph; Hshi-chi Koo; Yuchi Li; Jonathan M Davis Journal: Free Radic Biol Med Date: 2007-02-15 Impact factor: 7.376
Authors: Evert de Jonge; Linda Peelen; Peter J Keijzers; Hans Joore; Dylan de Lange; Peter H J van der Voort; Robert J Bosman; Ruud A L de Waal; Ronald Wesselink; Nicolette F de Keizer Journal: Crit Care Date: 2008-12-10 Impact factor: 9.097
Authors: Marta Martín-Fernández; María Heredia-Rodríguez; Paolo Pelosi; Jesús Villar; Eduardo Tamayo; Irene González-Jiménez; Mario Lorenzo-López; Estefanía Gómez-Pesquera; Rodrigo Poves-Álvarez; F Javier Álvarez; Pablo Jorge-Monjas; Juan Beltrán-DeHeredia; Eduardo Gutiérrez-Abejón; Francisco Herrera-Gómez; Gabriella Guzzo; Esther Gómez-Sánchez; Álvaro Tamayo-Velasco; Rocío Aller Journal: Crit Care Date: 2022-01-10 Impact factor: 9.097
Authors: Mervyn Singer; Paul J Young; John G Laffey; Pierre Asfar; Fabio Silvio Taccone; Markus B Skrifvars; Christian S Meyhoff; Peter Radermacher Journal: Crit Care Date: 2021-12-19 Impact factor: 9.097